vedolizumab
Showing 1 - 25 of 57
Crohn's Disease Trial in Chicago (Vedolizumab, Adalimumab, Ustekinumab)
Not yet recruiting
- Crohn's Disease
- Vedolizumab
- +2 more
-
Chicago, IllinoisUniversity of Chicago Medicine
Sep 13, 2023
Ulcerative Colitis Trial in Los Angeles (Vedolizumab, Tofacitinib)
Not yet recruiting
- Ulcerative Colitis
- Vedolizumab
- Tofacitinib
-
Los Angeles, CaliforniaCedars Sinai Medical Center
Oct 18, 2023
Safety and Efficacy Trial in Suzhou (Basiliximab, Vedolizumab)
Recruiting
- Safety and Efficacy
- Basiliximab
- Vedolizumab
-
Suzhou, Jiangsu, ChinaThe First Affiliated Hospital of Soochow University
Sep 27, 2023
Immune-Mediated Colitis Trial in Herlev (Vedolizumab, Prednisolone)
Recruiting
- Immune-Mediated Colitis
- Vedolizumab
- Prednisolone
-
Herlev, DenmarkHerlev University Hospital
Aug 16, 2022
Ulcerative Colitis Trial in Zhengzhou (Vedolizumab)
Recruiting
- Ulcerative Colitis
- Vedolizumab
-
Zhengzhou, Hangzhou, ChinaSecond Affiliated Hospital Zhejiang University School of Medicin
Jul 28, 2022
Vedolizumab for IV Infusion 300 mg [Ulcerative Colitis]
Recruiting
- Ulcerative Colitis
- Vedolizumab
-
Tokyo, JapanTakeda Selected Site
Apr 26, 2022
Colitis, Ulcerative Trial in Worldwide (Vedolizumab)
Recruiting
- Colitis, Ulcerative
- Vedolizumab
-
Minneapolis, MinnesotaMNGI Digestive Health, PA
Jan 21, 2022
IBD Trial in Kiel (Infliximab, Vedolizumab)
Completed
- IBD
- Infliximab
- Vedolizumab
-
Kiel, GermanyMedical Department I, University Hospital Schleswig-Holstein
Jun 30, 2022
Ulcerative Colitis, Crohn's Disease Trial in Japan (Vedolizumab)
Recruiting
- Ulcerative Colitis
- Crohn's Disease
- Vedolizumab
-
Toyota, Aichi, Japan
- +19 more
Jun 9, 2022
Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy Trial in
Recruiting
- Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma
- +2 more
- Vedolizumab
- +5 more
-
Beijing, Beijing, China
- +1 more
Nov 21, 2023
Crohn's Disease, Ulcerative Colitis, Inflammatory Bowel Disease Trial in Worldwide (Vedolizumab)
Completed
- Crohn's Disease
- +2 more
- Vedolizumab
-
Morristown, New Jersey
- +14 more
May 4, 2022
Crohn Disease Trial in France (Vedolizumab)
Recruiting
- Crohn Disease
- Vedolizumab
-
Paris, Le Kremlin-Bicêtre, France
- +4 more
Sep 20, 2021
A Multicentered Prospective Cohort Study of Chinese IBD Patients
Enrolling by invitation
- Ulcerative Colitis
- Crohn Disease
- Infliximab
- +3 more
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
May 17, 2022
Crohn's Disease and Ulcerative Colitis Trial in Seoul (Vedolizumab)
Not yet recruiting
- Crohn's Disease and Ulcerative Colitis
- Vedolizumab
-
Seoul, Korea, Republic ofYonsei University Health System, Severance Hospital
Jun 7, 2021
Ulcerative Colitis, Efficacy, Self, Biologics Trial in China (Infliximab, Vedolizumab, Mesalazine)
Not yet recruiting
- Ulcerative Colitis
- +3 more
- Infliximab
- +2 more
-
Chongqing, Chongqing, China
- +10 more
Jan 11, 2022
Colitis, Ulcerative, Crohn's Disease Trial in United States (Vedolizumab)
Completed
- Colitis, Ulcerative
- Crohn's Disease
- Vedolizumab
-
Aurora, Colorado
- +6 more
Dec 16, 2020
Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to
Terminated
- Ulcerative Colitis
- Vedolizumab
-
Stanford, California
- +1 more
Dec 17, 2020
Hematopoietic Stem Cells Trial in Worldwide (Vedolizumab, Vedolizumab Placebo)
Completed
- Hematopoietic Stem Cells
- Vedolizumab
- Vedolizumab Placebo
-
Birmingham, Alabama
- +138 more
Nov 2, 2022
Colitis, Ulcerative, Crohn Disease Trial in Cypress, Miami (Caffeine, Losartan, Omeprazole)
Withdrawn
- Colitis, Ulcerative
- Crohn Disease
- Caffeine
- +5 more
-
Cypress, California
- +1 more
Oct 23, 2020